Exchange Traded Concepts’s Pacira BioSciences PCRX Stock Holding History

Exchange Traded Concepts’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.51M	Buy	98,762 +1,476	+2%	+$34.9K	0.01%	637
2026 Q1	$2.2M	Buy	97,286 +20,448	+27%	+$454K	0.02%	579
2025 Q4	$1.99M	Buy	76,838 +1,240	+2%	+$29.5K	0.02%	593
2025 Q3	$1.95M	Buy	+75,598	New	+$1.86M	0.02%	580
2024 Q3	–	Sell	-51,480	Closed	-$1.47M	–	1404
2024 Q2	$1.47M	Buy	51,480 +2,788	+6%	+$79.3K	0.04%	372
2024 Q1	$1.42M	Buy	48,692 +33,515	+221%	+$1.03M	0.04%	365
2023 Q4	$512K	Hold	15,177	–	–	0.01%	624
2023 Q3	$466K	Buy	+15,177	New	+$547K	0.01%	631
2022 Q3	–	Sell	-9,355	Closed	-$545K	–	1277
2022 Q2	$545K	Buy	9,355 +212	+2%	+$13.9K	0.02%	481
2022 Q1	$698K	Sell	9,143 -541	-6%	-$36.1K	0.01%	410
2021 Q4	$583K	Buy	9,684 +174	+2%	+$9.59K	0.01%	561
2021 Q3	$533K	Buy	+9,510	New	+$548K	0.01%	539

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Exchange Traded Concepts's PCRX Position: Q2 2026 in Review

Exchange Traded Concepts increased its Pacira BioSciences (PCRX) stake by 1.5% in Q2 2026, buying an estimated $34.9K and bringing the position to 98,762 shares worth $2.51M. The position accounts for 0.01% of the portfolio, ranked #637.

Exchange Traded Concepts first reported a position in PCRX in Q3 2021 and has held it in 12 quarters since. 254 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Exchange Traded Concepts held 98,762 shares of Pacira BioSciences worth $2.51M as of Q2 2026.
Exchange Traded Concepts bought 1,476 Pacira BioSciences shares in Q2 2026, an estimated $34.9K.
Pacira BioSciences made up 0.01% of Exchange Traded Concepts's portfolio in Q2 2026, its #637 holding.
Exchange Traded Concepts first reported a position in Pacira BioSciences in Q3 2021 and has held it in 12 quarters since.
254 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Exchange Traded Concepts's 13F filing for Q2 2026, filed 22 Jul 2026.